Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by 2019champson Sep 09, 2021 8:00am
172 Views
Post# 33830062

The money is in metablok, not ivermectin and others

The money is in metablok, not ivermectin and othersOver the last several months, ivermectin has come up as a potential treatment for covid. The problem with that is, ivermectin is such a cheap treatment. No matter how effective it is, mainstream media and big pharma will never push such treatment. Pharma is looking to cash in on this pandemic. Governments are looking to use this pandemic to their advantag. Ivermectin isn't going to do that. Not to mention, ivermectin doesn't block inflammation and probably doesn't help with severe cases of covid. Metablok on the other hand is a big money treatment imo (if it works, which all signs point to being the case), and the liberals here in canada can potentially use it to their advantage for re-election. This is great timing for us.
<< Previous
Bullboard Posts
Next >>